Sökning: WFRF:(Castellano Daniel)
> (2011-2014) >
The role of RANK-li...
The role of RANK-ligand inhibition in cancer : the story of denosumab
-
- Castellano, Daniel (författare)
- 12 de Octubre University Hospital
-
- Sepulveda, Juan Manuel (författare)
- 12 de Octubre University Hospital
-
- García-Escobar, Ignacio (författare)
- 12 de Octubre University Hospital
-
visa fler...
-
- Rodriguez-Antolín, Alfredo (författare)
- 12 de Octubre University Hospital
-
- Sundlöv, Anna (författare)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Cortes-Funes, Hernán (författare)
- 12 de Octubre University Hospital
-
visa färre...
-
(creator_code:org_t)
- 2011-02-01
- 2011
- Engelska.
-
Ingår i: The Oncologist. - : Oxford University Press (OUP). - 1549-490X .- 1083-7159. ; 16:2, s. 45-136
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://europepmc.or...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases-bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Bone Neoplasms
- Bone Remodeling
- Breast Neoplasms
- Clinical Trials as Topic
- Denosumab
- Humans
- Male
- Multiple Myeloma
- Osteoclasts
- Prostatic Neoplasms
- RANK Ligand
- Receptor Activator of Nuclear Factor-kappa B
- Treatment Outcome
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas